Almost exactly a year after AstraZeneca plc quit its deal with NicOx SA for COX-inhibiting nitric oxide-donating (CINOD) drugs, NicOx said it expects to net about €24 million (US$29.8 million) through a private placement that will be used mainly to advance a lead compound from that program. (BioWorld International) Read More
